Literature DB >> 32976832

LncRNA regulation: New frontiers in epigenetic solutions to drug chemoresistance.

Ying Zhou1, Wen Sun1, Zhiyuan Qin1, Suhang Guo1, Yu Kang1, Su Zeng1, Lushan Yu2.   

Abstract

Long-noncoding RNAs (lncRNAs) have been shown to participate in sensitizing or de-sensitizing cancer cells to chemical drugs during cancer therapeutics. Notably, a plethora of lncRNAs have been confirmed to be associated with epigenetic controllers and regulate histone protein modification or DNA methylation states in the process of gene transcription. This correlation between lncRNAs and epigenetic regulators can induce the expression of core genes to trigger drug resistance. In addition, epigenetic signatures are considered to be effective and attractive biomarkers for monitoring drug therapeutic effects because they are inheritable, dynamic, and reversible. Therefore, the regulatory mechanism between lncRNAs and epigenetic machinery can serve as a novel indicator and target to overcome or reverse drug resistance in cancer therapy. In this review, we also presented a curated selection of computational tools (including online databases and network analysis) in the area of epigenetics. A classic workflow for lncRNA expression network analysis is presented, providing guidance for non-bioinformaticians to identify significant correlation between lncRNAs and other biomolecules.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bioinformatics tools; Chemoresistance; Epigenetics; LncRNA

Year:  2020        PMID: 32976832     DOI: 10.1016/j.bcp.2020.114228

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  CAF-derived midkine promotes EMT and cisplatin resistance by upregulating lncRNA ST7-AS1 in gastric cancer.

Authors:  Ke-Da Yang; Ying Wang; Fan Zhang; Qing-Ling Li; Bai-Hua Luo; De-Yun Feng; Zhi-Jun Zeng
Journal:  Mol Cell Biochem       Date:  2022-05-19       Impact factor: 3.396

Review 2.  The Intersection of Acute Kidney Injury and Non-Coding RNAs: Inflammation.

Authors:  Bojun Li; Fangyou Lin; Yuqi Xia; Zehua Ye; Xinzhou Yan; Baofeng Song; Tianhui Yuan; Lei Li; Xiangjun Zhou; Weimin Yu; Fan Cheng
Journal:  Front Physiol       Date:  2022-06-09       Impact factor: 4.755

3.  Long non-coding RNA SLC25A25-AS1 exhibits oncogenic roles in non-small cell lung cancer by regulating the microRNA-195-5p/ITGA2 axis.

Authors:  Jinqin Chen; Chengpeng Gao; Wei Zhu
Journal:  Oncol Lett       Date:  2021-05-16       Impact factor: 2.967

4.  RNA therapeutics: From biochemical pharmacology to technology development and clinical applications.

Authors:  Baitang Ning; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2021-04-16       Impact factor: 6.100

Review 5.  Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance.

Authors:  Guo-Hua Li; Qiang Qu; Ting-Ting Qi; Xin-Qi Teng; Hai-Hong Zhu; Jiao-Jiao Wang; Qiong Lu; Jian Qu
Journal:  J Exp Clin Cancer Res       Date:  2021-05-19

Review 6.  Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells.

Authors:  Ghazaleh Khalili-Tanha; Meysam Moghbeli
Journal:  Cell Mol Biol Lett       Date:  2021-08-23       Impact factor: 5.787

7.  Long noncoding RNA CEBPA-DT promotes cisplatin chemo-resistance through CEBPA/BCL2 mediated apoptosis in oral squamous cellular cancer.

Authors:  Xue Qiao; Jiayi Liu; Li Zhu; Rongbo Song; Ming Zhong; Yan Guo
Journal:  Int J Med Sci       Date:  2021-09-27       Impact factor: 3.738

Review 8.  Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma.

Authors:  José A Peña-Flores; Mercedes Bermúdez; Rosalío Ramos-Payán; Carlos E Villegas-Mercado; Uriel Soto-Barreras; Daniela Muela-Campos; Alexis Álvarez-Ramírez; Brenda Pérez-Aguirre; Ana D Larrinua-Pacheco; César López-Camarillo; Jorge A López-Gutiérrez; Julio Garnica-Palazuelos; Marvin E Estrada-Macías; Juan L Cota-Quintero; Andrés A Barraza-Gómez
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

9.  Dysregulation of Pseudogenes/lncRNA-Hsa-miR-1-3p-PAICS Pathway Promotes the Development of NSCLC.

Authors:  Yichen Song; Zhiying Wang; Lewei He; Feidi Sun; Beilei Zhang; Fu Wang
Journal:  J Oncol       Date:  2022-08-30       Impact factor: 4.501

10.  DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis.

Authors:  Xu Zhao; Jizhao Wang; Rui Zhu; Jing Zhang; Yunfeng Zhang
Journal:  Sci Rep       Date:  2021-10-25       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.